WuXi Biologics
Offering End-to-End Solutions
WuXi Biologics offers extensive and integrated Pre-Clinical Candidates (PCC) screening studies in the evaluation and selection of lead antibody therapeutics such as monoclonal (mAb), bispecific (bsAb), and multispecific antibodies or other biopharmaceutical candidates. PCC is just one part of our wide-ranging antibody discovery services and integrated development platforms from concept to IND.